Patents by Inventor Norihisa OHTAKE

Norihisa OHTAKE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220178932
    Abstract: An object of the invention is to provide a method for detecting cancer in a simple and highly accurate manner, and a reagent that can be used in the method. A method for detecting cancer (excluding renal cell cancer), which comprises measuring the level of Azurocidin (AZU1) in a sample, in which it is determined that cancer is detected when a measured value exceeds a preset reference value. The cancer is preferably selected from the group consisting of stomach cancer, breast cancer, colorectal cancer, and lung cancer. A reagent containing an antibody that specifically recognizes AZU1 is used in detecting cancer (excluding renal cell cancer).
    Type: Application
    Filed: April 15, 2020
    Publication date: June 9, 2022
    Applicants: JAPANESE FOUNDATION FOR CANCER RESEARCH, OSAKA UNIVERSITY, TOSOH CORPORATION
    Inventors: Koji UEDA, Naomi OHNISHI, Kazutake TSUJIKAWA, Norio NONOMURA, Motohide UEMURA, Kentaro JINGUSHI, Norihisa OHTAKE, Yasutoshi KAWAI
  • Patent number: 11193936
    Abstract: The present invention aims to provide a method for detecting, with high sensitivity and specificity, ovarian clear cell adenocarcinoma, which is highly malignant, among benign and malignant ovarian tumors having various tissue types, and a reagent that can be used for the method. The present invention provides NT-TFPI2, which is a novel processed tissue factor pathway inhibitor 2 polypeptide, as a new detection marker for ovarian clear cell adenocarcinoma. The detection of ovarian clear cell adenocarcinoma is carried out by measuring the amount of NT-TFPI2, or the total amount of NT-TFPI2 and intact TFPI2. The reagent for detecting ovarian clear cell adenocarcinoma contains an antibody that specifically recognizes NT-TFPI2 and intact TFPI2.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: December 7, 2021
    Assignees: PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY, TOSOH CORPORATION
    Inventors: Noriaki Arakawa, Hisashi Hirano, Etsuko Miyagi, Norihisa Ohtake
  • Publication number: 20210190786
    Abstract: The present invention aims to provide a method for simply and highly accurately detecting castration-resistant prostate cancer (CRPC), and a reagent that can be used for this method. By measuring the level of GDF15 propeptide present in a sample as a novel detection marker for CRPC, acquisition of castration resistance in a prostate cancer patient during or after endocrine therapy is detected. An antibody that specifically recognizes GDF15 propeptide is included in the CRPC detection reagent.
    Type: Application
    Filed: February 23, 2017
    Publication date: June 24, 2021
    Applicants: PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY, TOSOH CORPORATION
    Inventors: Noriaki ARAKAWA, Hisashi HIRANO, Hiroji UEMURA, Yusuke ITO, Shohei MYOBA, Norihisa OHTAKE
  • Publication number: 20210063400
    Abstract: An object of the present invention is to provide a method for detecting renal cancer, and a reagent that can be used for the method. Provided is a method for detecting renal cancer, which includes measuring the amount of TFPI2 in a sample derived from a patient. An antibody that specifically recognizes NT-TFPI2 and intact TFPI2 is included in a detection reagent for renal cancer.
    Type: Application
    Filed: December 26, 2018
    Publication date: March 4, 2021
    Applicants: PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY, TOSOH CORPORATIO
    Inventors: Noriaki ARAKAWA, Hisashi HIRANO, Noboru NAKAIGAWA, Masahiro YAO, Norihisa OHTAKE
  • Publication number: 20200256872
    Abstract: The present invention provides a method for detecting cancer in a simple and highly accurate manner, and a reagent that can be used in the method. According to the present invention, cancer (excluding castration-resistant prostate cancer) is detected by measuring the intact growth and differentiation factor (GDF15) propeptide level, the GDF15 propeptide fragment level, or the total of the intact GDF15 propeptide level and the GDF15 propeptide fragment level, in a sample. The above described method for detecting cancer includes a method for detecting one or more selected from the group consisting of stomach cancer, pancreatic cancer, colorectal cancer, lung cancer, breast cancer and esophageal cancer, and a method for distinguishing and detecting non-small cell lung cancer and small cell lung cancer. Further, a reagent for detecting cancer includes an antibody that specifically recognizes GDF15 propeptide.
    Type: Application
    Filed: August 22, 2018
    Publication date: August 13, 2020
    Applicant: TOSOH CORPORATION
    Inventors: Shohei MYOBA, Norihisa OHTAKE
  • Publication number: 20190170754
    Abstract: The present invention aims to provide a method for detecting, with high sensitivity and specificity, ovarian clear cell adenocarcinoma, which is highly malignant, among benign and malignant ovarian tumors having various tissue types, and a reagent that can be used for the method. The present invention provides NT-TFPI2, which is a novel processed tissue factor pathway inhibitor 2 polypeptide, as a new detection marker for ovarian clear cell adenocarcinoma. The detection of ovarian clear cell adenocarcinoma is carried out by measuring the amount of NT-TFPI2, or the total amount of NT-TFPI2 and intact TFPI2. The reagent for detecting ovarian clear cell adenocarcinoma contains an antibody that specifically recognizes NT-TFPI2 and intact TFPI2.
    Type: Application
    Filed: February 11, 2019
    Publication date: June 6, 2019
    Applicants: PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY, TOSOH CORPORATION
    Inventors: Noriaki Arakawa, Hisashi Hirano, Etsuko Miyagi, Norihisa Ohtake
  • Publication number: 20190049464
    Abstract: Novel means capable of detecting an arteriosclerotic lesion in a body by a less invasive, simple method is disclosed. The method for detecting arteriosclerosis according to the present invention comprises measuring the myosin heavy chain 11 level in a blood sample isolated from a subject. A myosin heavy chain 11 level higher than that of a healthy individual is indicative of the presence of arteriosclerosis in the subject. Since the present invention enables detection of arteriosclerosis by a blood test, a less invasive, simple test can be carried out. Unlike methods for testing only particular regions such as carotid artery ultrasonography, the present invention is expected to reflect the conditions of blood vessels in the whole body.
    Type: Application
    Filed: February 15, 2017
    Publication date: February 14, 2019
    Applicants: Public University Corporation Yokohama City University, TOSOH CORPORATION
    Inventors: Utako YOKOYAMA, Yoshihiro ISHIKAWA, Noriaki ARAKAWA, Munetaka MASUDA, Tomoaki ISHIGAMI, Shin-ichi SUZUKI, Norihisa OHTAKE, Hiroki KOBORI
  • Publication number: 20170322218
    Abstract: The present invention aims to provide a method for detecting, with high sensitivity and specificity, ovarian clear cell adenocarcinoma, which is highly malignant, among benign and malignant ovarian tumors having various tissue types, and a reagent that can be used for the method. The present invention provides NT-TFPI2, which is a novel processed tissue factor pathway inhibitor 2 polypeptide, as a new detection marker for ovarian clear cell adenocarcinoma. The detection of ovarian clear cell adenocarcinoma is carried out by measuring the amount of NT-TFPI2, or the total amount of NT-TFPI2 and intact TFPI2. The reagent for detecting ovarian clear cell adenocarcinoma contains an antibody that specifically recognizes NT-TFPI2 and intact TFPI2.
    Type: Application
    Filed: November 26, 2015
    Publication date: November 9, 2017
    Applicants: PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY, TOSOH CORPORATION
    Inventors: Noriaki ARAKAWA, Hisashi HIRANO, Etsuko MIYAGI, Norihisa OHTAKE